[
  {
    "ts": null,
    "headline": "Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market",
    "summary": "The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $414.86, representing a -1.49% change from its previous close.",
    "url": "https://finnhub.io/api/news?id=ea13f45ffd78cbd7d0bcc69d6aa27363baba0ef225ad1a52b775a7732ba999b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760047207,
      "headline": "Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market",
      "id": 137041873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $414.86, representing a -1.49% change from its previous close.",
      "url": "https://finnhub.io/api/news?id=ea13f45ffd78cbd7d0bcc69d6aa27363baba0ef225ad1a52b775a7732ba999b5"
    }
  },
  {
    "ts": null,
    "headline": "Is Vertex Stock Poised for Growth After Positive CRISPR Therapy Trial Results in 2025?",
    "summary": "If you're holding shares of Vertex Pharmaceuticals or thinking about adding some to your portfolio, you're not alone in wondering what the right move is. The stock's recent momentum may have caught your eye. Over just the past week, Vertex is up 4.2%, adding to a solid 6.6% gain across the last 30 days. While the year-to-date return stands at a modest 3.8%, there's meaningful long-term growth baked in, with a 45.2% gain over three years and 55.1% over five. Of course, that doesn't make up for...",
    "url": "https://finnhub.io/api/news?id=f9d2ba45332fae8090baadf4ff25423fb5c117e992951cb20d4a5c2d213e0726",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760029804,
      "headline": "Is Vertex Stock Poised for Growth After Positive CRISPR Therapy Trial Results in 2025?",
      "id": 137033443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "If you're holding shares of Vertex Pharmaceuticals or thinking about adding some to your portfolio, you're not alone in wondering what the right move is. The stock's recent momentum may have caught your eye. Over just the past week, Vertex is up 4.2%, adding to a solid 6.6% gain across the last 30 days. While the year-to-date return stands at a modest 3.8%, there's meaningful long-term growth baked in, with a 45.2% gain over three years and 55.1% over five. Of course, that doesn't make up for...",
      "url": "https://finnhub.io/api/news?id=f9d2ba45332fae8090baadf4ff25423fb5c117e992951cb20d4a5c2d213e0726"
    }
  },
  {
    "ts": null,
    "headline": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings",
    "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=3fbd195c73a91db415c2ff338e8ec041fd8e1dea47d09417c3de398e2c8949b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760014804,
      "headline": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings",
      "id": 137033444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=3fbd195c73a91db415c2ff338e8ec041fd8e1dea47d09417c3de398e2c8949b3"
    }
  },
  {
    "ts": null,
    "headline": "Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors",
    "summary": "BOSTON, October 09, 2025--Odyssey announces appointment of Nia Tatsis, Ph.D., EVP of Vertex Pharmaceuticals, to its Board of Directors.",
    "url": "https://finnhub.io/api/news?id=e1094b1d8e267a468020787ca64241b37ee14bf882442fb301e2f972d23154da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760011200,
      "headline": "Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors",
      "id": 137031316,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, October 09, 2025--Odyssey announces appointment of Nia Tatsis, Ph.D., EVP of Vertex Pharmaceuticals, to its Board of Directors.",
      "url": "https://finnhub.io/api/news?id=e1094b1d8e267a468020787ca64241b37ee14bf882442fb301e2f972d23154da"
    }
  },
  {
    "ts": null,
    "headline": "CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains?",
    "summary": "CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
    "url": "https://finnhub.io/api/news?id=08a7713b4cf12c366642be8eb5d590638c144556bb38296907384fa8cf39a155",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760000760,
      "headline": "CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains?",
      "id": 137030589,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
      "url": "https://finnhub.io/api/news?id=08a7713b4cf12c366642be8eb5d590638c144556bb38296907384fa8cf39a155"
    }
  }
]